Patent SG-11201909715V-A (SG)
Title: Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
Inventor: KELEMEN PETER
IPC: A61P35/00
Filed: 2018-05-30
Abstract: OO O O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 06 December 2018 (06.12.2018) WIPO I PCT ill mu °million ono mum VIII VIII 110 111110 oimIE (10) International Publication Number WO 2018/220040 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/28 (2006.01) A61K 31/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/064229 (22) International Filing Date: 30 May 2018 (30.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17173712.5 31 May 2017 (31.05.2017) EP (71) Applicant: MORPHOSYS AG [DE/DE]; Semmelweis- strasse 7, 82152 Planegg (DE). (72) Inventors: KELEMEN, Peter; MorphoSys AG, Semmel- weisstr. 7, 82152 Planegg (DE). SCHWARZ, Michael; MorphoSys AG, Semmelweisstr. 7, 82152 Planegg (DE). WINDERLICH, Mark; MorphoSys AG, Semmelweisstr. 7, 82152 Planegg (DE). HEEGER, Steffen; Richard-Wag- ner StraBe 56, 68165 Mannheim (DE). WEINELT, Do- minika; MorphoSys AG, Semmelweisstr. 7, 82152 Planegg (DE). (74) Agent: SPIELER, Stephan; Semmelweisstr. 7, 82152 Planegg (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT Figure 1 20mg 50mg 100mg 200mg 400rng C101 D8 D15 D22 D8 C2D1 (57) : The present disclosure provides anti-CD19 antibodies and venetoclax for use in the treatment of non-Hodgkin's lym- phoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma. The anti-CD19 antibodies, in particular MOR00208, and venetoclax are administered to patients suffering non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.